Karyopharm Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 325
- Market Cap
- -
- Introduction
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Clinical Trials
46
Trial Phases
2 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (46 trials with phase data)• Click on a phase to view related trials
News
Comprehensive Pipeline Analysis Reveals 200+ Investigational Drugs for Metastatic Hormone Refractory Prostate Cancer
A new comprehensive report analyzes over 200 pipeline drugs from 180+ companies targeting metastatic hormone refractory prostate cancer, highlighting the extensive research efforts in this challenging therapeutic area.
Promising Pipeline for Soft Tissue Sarcoma Treatment Expands with 130+ Therapies in Development
Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.
Xpovio Secures Public Health Insurance Coverage in Taiwan for Relapsed/Refractory Multiple Myeloma
• Antengene's Xpovio (selinexor), the world's first oral XPO1 inhibitor, will be included in Taiwan's National Health Insurance reimbursement scheme starting March 1, 2025, benefiting patients with relapsed/refractory multiple myeloma. • Multiple myeloma represents the second most common hematologic malignancy in Taiwan, with 700-800 new diagnoses and approximately 400 deaths annually, creating significant treatment challenges for patients. • Taiwan becomes the fifth APAC market to provide public insurance coverage for Xpovio, following mainland China, South Korea, Australia, and Singapore, with Antengene pursuing additional indications including myelofibrosis and endometrial cancer.
Karyopharm's Selinexor Shows Promise in Myelofibrosis, Phase 3 Data Expected in 2H 2025
Karyopharm Therapeutics anticipates top-line results from its Phase 3 SENTRY trial of selinexor plus ruxolitinib for JAKi-naïve myelofibrosis in the second half of 2025.
Karyopharm Announces FDA Discussions Regarding Selinexor's Endometrial Cancer Program
Karyopharm Therapeutics is engaging with the FDA to discuss the evolving treatment landscape in endometrial cancer and its impact on the Phase 3 XPORT-EC-042 trial.
Selinexor Data in Multiple Myeloma and Myelofibrosis to Be Presented at ASH 2024
Karyopharm will present data on selinexor in relapsed or refractory multiple myeloma (RRMM) at the ASH Annual Meeting.
Karyopharm Announces Favorable Study Design Update for Phase 3 SENTRY Trial in JAKi-Naive Myelofibrosis
Karyopharm Therapeutics announced a favorable study design update for its pivotal Phase 3 SENTRY trial evaluating selinexor in JAKi-naive myelofibrosis patients.
Iovance's MDA-TIL Trial Terminated, Sention's ST-1891 Phase II Completed
Iovance Biotherapeutics' MDA-TIL Phase II trial was terminated due to lack of efficacy, significantly decreasing its Phase Transition Success Rate (PTSR) in ovarian, colorectal, and pancreatic cancers.
Selinexor Shows Significant Survival Benefits in Multiple Myeloma Subgroups from BOSTON Trial
New subgroup analyses from the Phase 3 BOSTON trial demonstrate that selinexor plus bortezomib and dexamethasone (SVd) achieved a median progression-free survival of 29.5 months versus 9.7 months with bortezomib and dexamethasone alone in proteasome inhibitor-naïve patients.
Karyopharm Initiates Phase 1/2 Trial of Selinexor in Glioblastoma
Karyopharm Therapeutics has begun a Phase 1/2 clinical trial evaluating oral selinexor combined with standard care for newly diagnosed or recurrent glioblastoma (GBM).